The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Astra and Merck & Co present mixed small-cell lung cancer data, while Innovent, Xencor, Alphamab and Alligator bang the drum for CTLA-4.